CClinicalTrials.gg
CompletedNCT05126134VATEDUpdated Jul 29, 2022

Psychological Vulnerabilities and Transgender Adolescents: A Descriptive Epidemiology Study

An observational study in Gender Dysphoria, Adolescent, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2022-07-29.

Sponsored by University Hospital, Toulouse · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
15
Ages
12 Years to 18 Years
Sex
All
01

Study summary

The number of adolescents engaging in a transidentity journey has been increasing rapidly over the last decade. However, the knowledge of the medical world concerning the specificities of these adolescents is still too little in France. The objective of this study is to refine the knowledge of the different health care providers who are brought to meet these adolescents. This research proposes to study more specifically the register of psychological vulnerabilities: to cite only a few examplesThese include disorders such as depression, anxiety disorders and eating disorders, all of which cause suffering and difficulties in everyday life. A better understanding of the presence or absence and the distribution of these different types of vulnerabilities among transgender adolescents would allow, among other things, to promote their their screening by health care providers. This better screening would allow doctors to physicians to offer targeted treatment for these disorders in parallel with the transition process. transition process.

02

Conditions studied

  • Gender Dysphoria, Adolescent

Browse trials for

Keywords

  • mental disorders
03

In context

Gender Dysphoria

83 studies on the registry are indexed under Gender Dysphoria; 37 are open to participants now.

This study's enrollment of 15 is below the median of 100 across 52 observational studies indexed under Gender Dysphoria.

Browse Gender Dysphoria studies →

Lead sponsor

University Hospital, Toulouse is the lead sponsor of 794 studies on the registry; 214 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

adolescents receiving follow-up in a specialized consultation on gender dysphoria

Inclusion criteria

  • Be between 12 and 18 years old
  • Be followed up at the gender consultation of the Toulouse University Hospital

Exclusion criteria

Exclusion Criteria:

  • Have not yet completed the first consultation on gender issues at the time of selection.
  • Have only one last appointment with the gender consultation at the time of selection
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
15 participants (actual)
Patient registry
No

Groups and cohorts

  • adolescents followed for gender dysphoria

    The data collection by the examiner takes place during a single interview centered around the child's completion of a semi-structured questionnaire: the Kiddie Schedule for Affective Disorders and Schizophrenia. The child is interviewed alone and then with an accompanying parent.

    Diagnostic Test: KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)

Interventions

  • Diagnostic testKSADS (Kiddie Schedule for Affective Disorders and Schizophrenia)

    completion of the semi-structured questionnaire: the KSADS (Kiddie Schedule for Affective Disorders and Schizophrenia). The duration is 1h30 to 2h

06

What researchers measure

Primary outcomes

  1. list of diagnoses of mental disorders

    description of the prevalence of psychiatric comorbidities present in adolescents receiving follow-up in a specialized consultation on gender dysphoria using Diagnostic and Statistical Manual of Mental Disorders 5

    Time frame: enrollment

07

Study locations

1 site
  • Chu Toulouse
    Toulouse, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05126134
Lead sponsor
University Hospital, Toulouse
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
Nov 26, 2021
Primary completion
Jun 3, 2022
Completion
Jun 3, 2022
Last update
Jul 29, 2022

Study contacts

Sophie Çabal-Berthoumieu, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion